Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.390
-0.130 (-2.88%)
At close: Apr 28, 2026, 4:00 PM EDT
4.620
+0.230 (5.24%)
After-hours: Apr 28, 2026, 7:54 PM EDT
Prelude Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 441 | 239 | 97 | 323 | 287 | 577 | |
| Market Cap Growth | 805.15% | 147.03% | -70.04% | 12.32% | -50.21% | -80.97% | |
| Enterprise Value | 356 | 202 | -39 | 93 | 65 | 259 | |
| Last Close Price | 4.39 | 2.90 | 1.27 | 4.27 | 6.04 | 12.45 | |
| PS Ratio | 36.36 | 19.68 | 13.82 | - | - | - | |
| PB Ratio | 5.28 | 3.48 | 0.74 | 1.36 | 1.47 | 2.02 | |
| P/TBV Ratio | 6.43 | 3.48 | 0.74 | 1.36 | 1.47 | 2.02 | |
| EV/Sales Ratio | 29.32 | 16.63 | - | - | - | - | |
| Debt / Equity Ratio | 0.26 | 0.26 | 0.14 | 0.07 | 0.01 | 0.01 | |
| Net Debt / Equity Ratio | -1.25 | -1.25 | -0.88 | -0.91 | -1.02 | -1.01 | |
| Net Debt / EBITDA Ratio | 0.84 | 0.84 | 0.84 | 1.65 | 1.64 | 2.57 | |
| Net Debt / FCF Ratio | 1.52 | 1.52 | 1.12 | 1.95 | 2.30 | 3.37 | |
| Asset Turnover | 0.08 | 0.08 | 0.03 | - | - | - | |
| Quick Ratio | 1.95 | 1.95 | 5.21 | 10.67 | 9.30 | 15.17 | |
| Current Ratio | 1.99 | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | |
| Return on Equity (ROE) | -99.45% | -99.45% | -69.01% | -56.34% | -47.97% | -44.85% | |
| Return on Assets (ROA) | -40.74% | -40.74% | -38.54% | -33.19% | -29.38% | -26.89% | |
| Return on Capital Employed (ROCE) | -116.90% | -116.90% | -93.20% | -51.70% | -62.10% | -39.80% | |
| Earnings Yield | -22.54% | -41.64% | -131.47% | -37.74% | -40.16% | -19.35% | |
| FCF Yield | -12.77% | -23.59% | -107.16% | -34.25% | -30.18% | -14.87% | |
| Buyback Yield / Dilution | -1.52% | -1.52% | -25.60% | -27.41% | -2.87% | -269.03% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.